CYY292 |
| Katalog-Nr.GC91419 |
CYY292 ist ein Inhibitor von PDGFRα, PDGFRβ, FGFR1,-2 und -3 (IC50s = 5,35, 4,6, 28, 28 bzw. 78 nM).
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2644673-04-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
CYY292 is an inhibitor of PDGFRα, PDGFRβ, FGFR1, -2, and -3, (IC50s = 5.35, 4.6, 28, 28, and 78 nM, respectively).1,2 It is selective for these kinases over FGFR4 (IC50 = >1,000 nM) but also inhibits c-Kit, VEGFR2, VEGFR1, and insulin-like growth factor 1 receptor (IGF-1R; IC50s = 67, 33, 36, and 75 nM, respectively), as well as EGFR, Bruton's tyrosine kinase (BTK), cyclin-dependent kinase 4 (Cdk4)/cyclin D3, and MET (IC50s = 128, 198, 214, and 396 nM, respectively).2 CYY292 inhibits the proliferation of MG-63, U2OS, MNNG/HOS, and Saos-2 osteosarcoma cells (IC50s = 0.84, 0.76, 1.36, and 0.72 µM, respectively).1 It inhibits the migration and invasion of U87MG and LN-229 glioblastoma cells when used at concentrations of 0.3 and 0.5 µM.2 CYY292 (30 mg/kg) decreases tumor volume and increases survival in a U87MG orthotopic mouse xenograft model.
Review for CYY292
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
Review for CYY292
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *